text: Yo, check it out, we on a mission,
  Investigating thiotepa and fludarabine, no intermission,
  Preparative regimen for allogeneic transplant, listen,
  Patients not eligible for myeloablative, they in a tough position.
  
  Thiotepa, 10 mg/kg for two days straight,
  Fludarabine, 125 mg/m(2), five days, don't wait,
  21 patients, 14 dudes, seven ladies, fate,
  Ten acute leukemia, eight myelodysplastic, two lymphoma, one Hodgkin's, great.
  
  Median age, 51 years, 30-55 range,
  Full donor-type chimaerism, ain't nothin' strange,
  Few side effects like nausea, vomiting, it's a change,
  Slight increase in serum amylase, we gotta rearrange.
  
  RBC transfusions for 13 patients, 1-23 range,
  Platelets for all, 1-27, ain't that strange?
  Four died nonrelapse, five fell to relapse, the pain,
  But 12 in complete remission, holdin' on, no strain.
  
  Transplant-related mortality, 19% at one year,
  Relapse, 29%, that's somethin' to fear,
  Three-year overall survival, 58%, clear,
  Feasible and well tolerated, that's why we're here.
  
  Yo, this study shows the way,
  Thiotepa and fludarabine, don't play,
  For those not eligible, a chance to stay,
  Hope and healing, our mantra every day.